Announced
Synopsis
Junshi Biosciences, a China-based biotechnology company, agreed to invest $50m in Coherus BioSciences, a biotherapeutics company engaged in developing and commercializing biosimilar therapeutics. “We view our collaboration with Coherus as a strategic long-term partnership for the development and commercialization of toripalimab and promising PD-1 combination candidates. We wanted to invest in Coherus so we could share our future growth together and mutual success with these programs," Ning LI, Junshi Biosciences CEO.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.